Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04085523 · ClinicalTrials.gov registry record · Phase 2
A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia
A Phase 2 study, sponsored by Ascendis Pharma A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT04085523 is a Phase 2 study that has completed, run by Ascendis Pharma A/S. The registered enrollment target is 57 participants.
The verdict
NCT04085523, a Phase 2 study, has completed, sponsored by Ascendis Pharma A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
The trial is a multicenter, double-blind, randomized, placebo-controlled, dose escalation trial of weekly TransCon CNP administered subcutaneously in prepubertal children 2 to 10 years old, inclusive, with Achondroplasia.
Interventions
- DRUG TransCon CNP
- DRUG Placebo for TransCon CNP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2020-06-24 |
| Est. Completion | 2024-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04085523
The ClinicalTrials.gov registry entry for NCT04085523 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ascendis Pharma A/S, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TransCon CNP is the first listed.
NCT04085523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04085523 about?
NCT04085523 is a clinical study titled "A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of TransCon CNP Administered Once Weekly in Prepubertal Children With Achondroplasia". The trial is a multicenter, double-blind, randomized, placebo-controlled, dose escalation trial of weekly TransCon CNP administered subcutaneously in prepubertal children 2 to 10 years old, inclusive, with Achondroplasia.
What is the current status of trial NCT04085523?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2020-06-24. Estimated completion is 2024-10-01.
What interventions are being tested in trial NCT04085523?
The interventions under investigation include: TransCon CNP (DRUG), Placebo for TransCon CNP (DRUG).
Who is sponsoring clinical trial NCT04085523?
This trial is sponsored by Ascendis Pharma A/S, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.